Unknown

Dataset Information

2D-DIGE as a strategy to identify serum protein biomarkers to monitor pharmacological efficacy in dopamine-dictated states of Parkinson's disease and schizophrenia.


ABSTRACT:

Objectives

Parkinson's disease and schizophrenia are clinical scenarios that occur due to dopaminergic deficit and hyperactivity in the midbrain, respectively. Current pharmacological interventions for these two diseases therefore aim to restore normal dopamine levels in the midbrain. But during therapy, there is a overshooting of dopamine concentrations that result in hallucinations in Parkinson's disease patients and extra-pyramidal symptoms in schizophrenic patients. This causes a lot of inconvenience to the patents and the clinicians. There are no tests currently available to monitor drug efficacy in these two neuropsychiatric diseases.

Materials and methods

Parkinson's disease and schizophrenic naïve patients were recruited. Serum proteins isolated from these two clinic

SUBMITTER: Gupta AK 

PROVIDER: S-EPMC6488160 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature